Purine nucleotide cycle

The Purine Nucleotide Cycle is a metabolic pathway in protein metabolism requiring the amino acids aspartate and glutamate. The cycle is used to regulate the levels of adenine nucleotides, in which ammonia and fumarate are generated. AMP converts into IMP and the byproduct ammonia. IMP converts to S-AMP, which then converts to AMP and the byproduct fumarate. The fumarate goes on to produce ATP via oxidative phosphorylation as it enters the Krebs cycle and then the electron transport chain. Lowenstein first described this pathway and outlined its importance in processes including amino acid catabolism and regulation of flux through glycolysis and the Krebs cycle.
AMP is produced after strenuous muscle contraction when the ATP reservoir is low by the adenylate kinase reaction. AMP is also produced from adenine and adenosine directly; however, AMP can be produced through less direct metabolic pathways, such as de novo synthesis of IMP or through salvage pathways of guanine and any of the purine nucleotides and nucleosides. IMP is synthesized de novo from glucose through the pentose phosphate pathway which produces ribose 5-P, which then converts to PRPP that with the amino acids glycine, glutamine, and aspartate can be further converted into IMP.

Reactions

The cycle comprises three enzyme-catalysed reactions. The first stage is the deamination of the purine nucleotide adenosine monophosphate to form inosine monophosphate, catalysed by the enzyme AMP deaminase:
The second stage is the formation of adenylosuccinate from IMP and the amino acid aspartate, which is coupled to the energetically favourable hydrolysis of GTP, and catalysed by the enzyme adenylosuccinate synthetase:
Finally, adenylosuccinate is cleaved by the enzyme adenylosuccinate lyase to release fumarate and regenerate the starting material of AMP:
A recent study showed that activation of HIF-1α allows cardiomyocytes to sustain mitochondrial membrane potential during anoxic stress by utilizing fumarate produced by adenylosuccinate lyase as an alternate terminal electron acceptor in place of oxygen. This mechanism should help provide protection in the ischemic heart.

Occurrence

The purine nucleotide cycle occurs in the cytosol of the sarcoplasm of skeletal muscle, and in the myocyte's cytosolic compartment of the cytoplasm of cardiac and smooth muscle. The cycle occurs when ATP reservoirs run low, such as strenuous exercise, fasting or starvation.
Proteins catabolize into amino acids, and amino acids are precursors for purines, nucleotides and nucleosides which are used in the purine nucleotide cycle. The amino acid glutamate is used to neutralize the ammonia produced when AMP is converted into IMP. Another amino acid, aspartate, is used along with IMP to produce S-AMP in the cycle. Skeletal muscle contains amino acids for use in catabolism, known as the free amino acid pool; however, inadequate carbohydrate supply and/or strenuous exercise requires protein catabolism to sustain the free amino acids.
When the phosphagen system (ATP-PCr) has been depleted of phosphocreatine, the purine nucleotide cycle also helps to sustain the myokinase reaction by reducing accumulation of AMP produced after muscle contraction in the below reaction.
During muscle contraction:
Muscle at rest:
AMP can dephosphorylate to adenosine and diffuse out of the cell; the purine nucleotide cycle may therefore also reduce the loss of adenosine from the cell since nucleosides permeate cell membranes, whereas nucleotides do not.

Consequences

Aspartate and glutamate synthesis

, produced from the purine nucleotide cycle, is an intermediate of TCA cycle and enters the mitochondria by converting into malate and utilizing the malate shuttle where it is converted into oxaloacetic acid. During exercise, OAA either enters into TCA cycle or converts into aspartate in the mitochondria.
As the purine nucleotide cycle produces ammonia , skeletal muscle needs to synthesize glutamate in a way that does not further increase ammonia, and as such the use of glutaminase to produce glutamate from glutamine would not be ideal. Also, plasma glutamine requires active transport into the muscle cell. Consequently, during exercise when the ATP reservoir is low, glutamate is produced from branch-chained amino acids and α-ketoglutarate, as well as from alanine and α-ketoglutarate. Glutamate is then used to produce aspartate. The aspartate enters the purine nucleotide cycle, where it is used to convert IMP into S-AMP.
When skeletal muscle is at rest, the aspartate is no longer needed for the purine nucleotide cycle and can therefore be used with α-ketoglutarate to produce glutamate and oxaloacetic acid.

α-Ketoglutarate + Aspartate ⇌ Oxaloacetic acid + Glutamate

Ammonia and glutamine synthesis

During exercise when the ATP reservoir is low, the purine nucleotide cycle produces ammonia when it converts AMP into IMP.. During rest, ammonia is produced from the conversion of adenosine into inosine by adenosine deaminase.
Ammonia is toxic, disrupts cell function, and permeates cell membranes. Ammonia becomes ammonium depending on the pH of the cell or plasma. Ammonium is relatively non-toxic and does not readily permeate cell membranes.

+ ⇌

Ammonia diffuses into the blood, circulating to the liver to be neutralized by the urea cycle. When the skeletal muscles are at rest, ammonia combines with glutamate to produce glutamine, which is an energy-consuming step, and the glutamine enters the blood.

Glutamate + + ATP → Glutamine + ADP +

Excess glutamine is used by proximal tubule in the kidneys for ammoniagenesis, which may counteract any metabolic acidosis from anaerobic skeletal muscle activity. In kidneys, glutamine is deaminated twice to form glutamate and then α-ketoglutarate. These molecules neutralise the organic acids produced in the muscles.

Glutamine + → Glutamate +

Pathology

Some metabolic myopathies involve the under- or over-utilization of the purine nucleotide cycle. Metabolic myopathies cause a low ATP reservoir in muscle cells, resulting in exercise-induced excessive AMP buildup in muscle, and subsequent exercise-induced hyperuricemia through conversion of excessive AMP into uric acid by way of either AMP → adenosine or AMP → IMP.
During strenuous exercise, AMP is created through the use of the adenylate kinase reaction after the phosphagen system has been depleted of creatine phosphate and not enough ATP is being produced yet by other pathways . In those affected by metabolic myopathies, exercise that normally wouldn't be considered strenuous for healthy people, is however strenuous for them due to their low ATP reservoir in muscle cells. This results in regular use of the myokinase reaction for normal, everyday activities.
Besides the myokinase reaction, a high ATP consumption and low ATP reservoir also increases protein catabolism and salvage of IMP, which results in increased AMP and IMP. These two nucleotides can then enter the purine nucleotide cycle to produce fumarate which will then produce ATP by oxidative phosphorylation. If the purine nucleotide cycle is blocked or if exercise is stopped and increased fumarate production is no longer needed, then the excess nucleotides will be converted into uric acid.

AMP deaminase deficiency (MADD)

is a metabolic myopathy which results in excessive AMP buildup brought on by exercise. AMP deaminase is needed to convert AMP into IMP in the purine nucleotide cycle. Without this enzyme, the excessive AMP buildup is initially due to the adenylate kinase reaction which occurs after a muscle contraction. However, AMP is also used to allosterically regulate the enzyme myophosphorylase, so the initial buildup of AMP triggers the enzyme myophosphorylase to release muscle glycogen into glucose-1-P, which eventually depletes the muscle glycogen, which in turn triggers protein metabolism, which then produces even more AMP. In AMP deaminase deficiency, excess adenosine is converted into uric acid in the following reaction:

Glycogenoses (GSDs)

Myogenic hyperuricemia, as a result of the purine nucleotide cycle running when ATP reservoirs in muscle cells are low, is a common pathophysiologic feature of glycogenoses such as Glycogen [storage disease type III|GSD-III], GSD-V and GSD-VII, as they are metabolic myopathies which impair the ability of ATP production within muscle cells. In these metabolic myopathies, myogenic hyperuricemia is exercise-induced; inosine, hypoxanthine and uric acid increase in plasma after exercise and decrease over hours with rest. Excess AMP (adenosine monophosphate) is converted into uric acid.
Hyperammonemia is also seen post-exercise in McArdle disease and phosphoglucomutase deficiency, due to the purine nucleotide cycle running when the ATP reservoir is low due to the glycolytic block.

AMP + + → IMP +